VIRX vs. PMN, ACXP, ELDN, MRKR, NRXP, KRRO, RMTI, VTVT, NXTC, and DRRX
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include ProMIS Neurosciences (PMN), Acurx Pharmaceuticals (ACXP), Eledon Pharmaceuticals (ELDN), Marker Therapeutics (MRKR), NRx Pharmaceuticals (NRXP), Korro Bio (KRRO), Rockwell Medical (RMTI), vTv Therapeutics (VTVT), NextCure (NXTC), and DURECT (DRRX). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
25.8% of Viracta Therapeutics shares are held by institutional investors. Comparatively, 2.2% of ProMIS Neurosciences shares are held by institutional investors. 7.4% of Viracta Therapeutics shares are held by insiders. Comparatively, 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Viracta Therapeutics received 22 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 70.59% of users gave Viracta Therapeutics an outperform vote.
ProMIS Neurosciences has higher revenue and earnings than Viracta Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viracta Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
ProMIS Neurosciences' return on equity of 0.00% beat Viracta Therapeutics' return on equity.
In the previous week, Viracta Therapeutics had 5 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 5 mentions for Viracta Therapeutics and 0 mentions for ProMIS Neurosciences. Viracta Therapeutics' average media sentiment score of 1.05 beat ProMIS Neurosciences' score of 0.93 indicating that Viracta Therapeutics is being referred to more favorably in the media.
Viracta Therapeutics presently has a consensus price target of $7.75, indicating a potential upside of 682.83%. ProMIS Neurosciences has a consensus price target of $8.00, indicating a potential upside of 318.85%. Given Viracta Therapeutics' higher probable upside, analysts clearly believe Viracta Therapeutics is more favorable than ProMIS Neurosciences.
Summary
Viracta Therapeutics beats ProMIS Neurosciences on 10 of the 15 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Viracta Therapeutics Competitors List
Related Companies and Tools